Why Lower Drug Prices Benefit Institutional Investors General ReflectionsAdam SeitchikMay 25, 2007Drug prices, fiduciary duty, health care costs, pharmaceutical pricing, shareholder activism, shareholder resolutions, socially responsible investing, universal ownersComment
